| Literature DB >> 35458117 |
Sharifah Saffinas Syed Soffian1, Azmawati Mohammed Nawi1, Rozita Hod1, Mohd Hasni Ja'afar1, Zaleha Md Isa1, Huan-Keat Chan2, Muhammad Radzi Abu Hassan2.
Abstract
The Dietary Inflammatory Index (DII) was extensively used to examine the inflammatory potential of diet related to colorectal cancer (CRC). This meta-analysis aimed to update the evidence of the association between the DII and CRC across various culture-specific dietary patterns. Literature search was performed through online databases (Scopus, Web of Science, PubMed, and EBSCOHost). Observational studies exploring the association between the DII and CRC, published between 2017 and 2021, were included. The risk ratio (RR) and 95% confidence interval (CI) were separately computed for 12 studies comparing the highest and lowest DII scores and for 3 studies that presented continuous DII scores. A high DII score was associated with a higher risk of CRC (RR:1.16; 95% CI, 1.05-1.27). In the subgroup analysis, significant associations were seen in cohort design (RR: 1.24; 95% CI, 1.06-1.44), those lasting for 10 years or longer (RR: 2.95; 95% CI, 2.47-3.52), and in adjustment factor for physical activity (RR: 1.13; 95% CI, 1.07-1.20). An increase of one point in the DII score elevates the risk of CRC by 1.34 (95% CI: 1.15-1.55) times. The findings call for standardized measurement of the inflammatory potential of diet in future studies to enable the establishment of global guidelines for CRC prevention.Entities:
Keywords: Dietary Inflammatory Index; colorectal cancer; dietary pattern; modifiable risk factor
Mesh:
Year: 2022 PMID: 35458117 PMCID: PMC9031004 DOI: 10.3390/nu14081555
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1PRISMA flowchart.
Keyword search used in the identification process.
| Database | Search String |
|---|---|
|
| TITLE-ABS-KEY ((“dietary inflammatory index” OR “dietary inflammatory score” OR “diet-related inflammation” OR “dietary inflammatory potential” OR “proinflammatory diet” OR “anti-inflammatory diet”) AND (“colorectal cancer *” OR “colorectal neoplas *” OR “colorectal tumo * r” OR “colorectal malignanc *”)) |
|
| TS = ((“dietary inflammatory index” OR “dietary inflammatory score” OR “diet-related inflammation” OR “dietary inflammatory potential” OR “proinflammatory diet” OR “anti-inflammatory diet”) AND (“colorectal cancer *” OR “colorectal neoplas *” OR “colorectal tumo * r” OR “colorectal malignanc *”)) |
|
| ((“dietary inflammatory index” OR “dietary inflammatory score” OR “diet-related inflammation” OR “dietary inflammatory potential” OR “proinflammatory diet” OR “anti-inflammatory diet”) AND (“colorectal cancer” OR “colorectal neoplasm” OR “colorectal tumor” OR “colorectal tumour” OR “colorectal malignancy” OR “colorectal malignancies”)) |
|
| ((“dietary inflammatory index” OR “dietary inflammatory score” OR “diet-related inflammation” OR “dietary inflammatory potential” OR “proinflammatory diet” OR “anti-inflammatory diet”) AND (“colorectal cancer” OR “colorectal neoplasm” OR “colorectal tumor” OR “colorectal tumour” OR “colorectal malignancy” OR “colorectal malignancies”)) |
The symbol * is used in the search strategy as truncation and wildcard function for keywords variation purposes.
Quality appraisal of selected studies using Newcastle–Ottawa quality assessment scale for case control and cohort studies.
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
| ||
| Abulimi et al., 2020 [ | * | * | * | * | ** | - | * | - | 7 |
| Byrd et al., 2020 [ | * | * | * | * | ** | * | * | - | 8 |
| Cho et al., 2019 [ | - | * | - | * | ** | * | * | - | 6 |
| Niclis et al., 2018 [ | * | - | * | * | * | - | - | * | 5 |
| Obon-Santacana, 2019 [ | - | - | - | * | ** | - | * | - | 4 |
| Rafiee et al., 2019 [ | * | * | * | * | * | * | * | - | 7 |
| Sharma et al., 2017 [ | - | * | * | * | * | * | * | - | 6 |
| Shivappa et al., 2017 [ | * | * | - | * | * | * | * | - | 6 |
| Yuan et al., 2021 [ | * | * | - | * | * | * | * | - | 6 |
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
| ||
| Brouwer et al., 2017 [ | * | - | * | * | * | * | * | * | 7 |
| Harmon et al., 2017 [ | * | - | - | * | - | * | * | - | 4 |
| Ratjen et al., 2019 [ | * | - | * | * | - | * | * | * | 6 |
| Tabung et al., 2017 [ | * | * | * | * | * | * | * | * | 8 |
| Zheng et al., 2020 [ | * | - | * | * | * | * | * | * | 7 |
| Wesselink et al., 2021 [ | * | - | * | * | * | * | * | * | 7 |
* denotes the scoring of one star; ** represents the scoring of two stars that is also the maximum scoring for the comparability domain; *** represents the scoring of three stars and the maximum scoring for the outcome domain; **** represents the scoring of four stars and the maximum scoring for selection domain.
Data extracted from the studies included for meta-analysis.
| Author, Year | Study Location | Study Design | Study Period | Study Instrument | Number of Food Parameters | Sample Size | Range of DII Scores | Type of Data and Comparison | Measures of Association | Adjustment Factors |
|---|---|---|---|---|---|---|---|---|---|---|
| Abulimiti et al., 2020 [ | China | Case control | 2010–2019 | 81-item FFQ 1 | 34 | 2502 cases | −5.96 to +6.01 | Categorical | OR = 1.40 (95% CI 1.16, 1.68) | Age, sex, marital status, residence, education level, occupation, income, BMI 2, smoking status, family history of CRC, comorbidities |
| 2538 controls | Quartile 4 vs. Quartile 1 | |||||||||
| Brouwer et al., 2017 [ | Netherlands | Prospective cohort | 2006–2012 | 183-item FFQ | 28 | 457 | −11.7 to +8.4 | Categorical | HR = 1.37 (95% CI 0.80, 2.34; | Age, smoking status, education level |
| Tertile 3 (0.3 to 8.4) vs. Tertile 1 (−11.7 to <−1.8) | ||||||||||
| Byrd et al., 2020 [ | United States | Case control | 1991–2002 | 126-item FFQ | 19 | 765 cases | (controls): −0.7 ± 2.4 | Categorical | OR = 1.31 (95% CI 0.98, 1.75) | Age, sex, education, NSAIDs 3 use, hormone use, family history of CRC, smoking status, BMI, alcohol intake, physical activity |
| 1986 controls | (cases): −0.5 ± 2.4 | Quintile 5 vs. Quintile 1 | ||||||||
| Cho et al., 2019 [ | Korea | Case control | 2010–2013 | 106-item FFQ | 35 | 632 cases | (controls): 0.94 ± 2.24 | Categorical | OR = 1.38 (95% CI 1.12, 1.71) | Age, sex, family history of CRC, education level, BMI, physical activity, smoking status, alcohol intake |
| 1295 controls | (cases): 1.77 ± 1.97 | High vs. Low | ||||||||
| Harmon et al., 2017 [ | United States | Prospective cohort | 1993–2010 | 169-item FFQ | 28 | 190,963 | −6.64 to +4.95 | Categorical | HR = 1.21 (95% CI 1.11, 1.32) | Age, sex, race, comorbidities, smoking status, BMI, family history of CRC, education level, aspirin use, hormones use |
| Quartile 4 (−0.52 to 4.95) vs. Quartile 1 (−6.64 to −3.66) | ||||||||||
| Niclis et al., 2018 [ | Argentina | Case control | 2008–2015 | 127-item FFQ | 22 | 144 cases | −3.15 to +3.77 | Categorical | OR = 1.56 (95% CI 1.20, 2.03) | Age, sex, BMI, smoking status, socioeconomic status, physical activity, NSAIDs use |
| 302 controls | Tertile II (0.6–1.86) vs. Tertile 1 (<0.65) | |||||||||
| Obon-Santacana et al., 2019 [ | Spain | Case control | 2008–2013 | 140-item FFQ | 30 | 1852 cases | (men): −5.11 to 5.47 | Continuous DII (per one unit increase) | OR = 1.14 (95% CI 1.10, 1.18) | Sex, age, education level, study area, family history of CRC, smoking status, physical activity, BMI, NSAIDs use |
| 3447 controls | (women): −5.64 to 5.12 | |||||||||
| Rafiee et al., 2019 [ | Iran | Case control | 2017–2018 | 148-items FFQ | 21 | 134 cases | −4.23 to +3.89 | Categorical | OR = 2.64 (95% CI 1.40, 4.99) | Age, sex, physical activity, salt intake, comorbidities, smoking, family history of CRC, cooking method, supplement intake |
| 240 controls | Tertile 3 (>0.04) vs. Tertile 1 (<−1.13) | |||||||||
| Ratjen et al., 2019 [ | Germany | Prospective cohort | 2009–2011 | 112-item FFQ | 27 | 1404 | −3.99 to +4.11 | Continuous DII (per one unit increase) | HR = 1.08 (95% CI 0.97, 1.20) | Sex, age at diet assessment, BMI, physical activity, survival time, tumor location, metastasis, other type of cancers, therapy, smoking status, alcohol intake |
| Sharma et al., 2017 [ | Canada | Case control | 1999–2003 | 169-item FFQ | 29 | 547 cases | −5.19 to +6.93 | Categorical | OR = 1.65 (95% CI 1.13, 2.42) | Age, sex, BMI, physical activity, comorbidities, family history of CRC, smoking status, alcohol intake, NSAIDs use |
| 685 controls | Quartile 4 (≥0.3582) vs. Quartile 1 (<−2.036) | |||||||||
| Wesselink et al., 2021 [ | Netherlands | Prospective cohort | 2010–2017 | 204-item FFQ | 28 | 1478 | −12.2 to +8.5 | Categorical | HR = 0.98 (95% CI 0.94, 1.04; | Age, sex, staging, BMI, smoking status, NSAIDs use, comorbidities |
| Tertile 3 (1.2 to <8.5) vs. Tertile 1 (−12.2 to <−1.0) | ||||||||||
| Shivappa et al., 2017 [ | Jordan | Case control | 2010–2012 | 90-item FFQ | 18 | 153 cases | −2.25 to +2.86 | Continuous DII (per one unit increase) | OR = 1.45 (95% CI 1.13, 1.85) | Age, sex, education level, physical activity, BMI, smoking status, family history of CRC |
| 202 controls | ||||||||||
| Tabung et al., 2017 [ | United States | Prospective cohort | 1993–2014 | 122-item FFQ | 32 | 87,042 | −6.62 to +5.39 | Categorical | HR = 1.06 (95% CI 0.90, 1.26) | Age, race, education level, smoking status, comorbidities, regular NSAIDs use, estrogen use, BMI, physical activity |
| Quintiles 5 vs. Quintiles 1 | ||||||||||
| Yuan et al., 2021 [ | United States | Case control | 2005–2015 | 175-item FFQ | 34 | 587 cases | −5.9 to +4.6 | Continuous DII (per one unit increase) | OR = 1.07 (95% CI 0.97, 1.19) | Age, gender, race, BMI, education level, smoking status, comorbidities, NSAIDs use, family history of CRC, supplements use |
| 1313 controls | ||||||||||
| Zheng et al., 2020 [ | United States | Prospective cohort | 1993–2015 | 122-item FQ | 32 | 161,808 | −6.80 to +3.25 | Categorical | HR = 0.72 (95% CI 0.46, 1.12) | Age, race, smoking status, income levels, cancer staging, education level, physical activity, BMI |
| Tertile 1 | ||||||||||
| (−5.96 to −2.25) vs. Tertile 3 (−0.18 to 3.82) |
1 FFQ, food frequency questionnaire; 2 BMI, body mass index; NSAIDs 3, non-steroidal anti-inflammatory drugs.
Figure 2Forest plot for 12 studies comparing the risk of CRC between high (pro-inflammatory) and low (anti-inflammatory) scores.
Figure 3Forest plot for three studies relating the risk of CRC to continuous DII scores.
Subgroup analyses of studies reporting the risk for CRC between high (pro-inflammatory) and low (anti-inflammatory) scores.
| Subgroups | No. of Studies | RR (95% CI) | Heterogeneity | Significance Test | ||
|---|---|---|---|---|---|---|
| I2 (%) |
| Z |
| |||
| Study design | ||||||
| Case-control | 7 | 1.14 (0.89, 1.45) | 81% | 0.000 | 1.03 | 0.300 |
| Cohort | 4 | 1.24 (1.06, 1.44) | 63% | 0.030 | 2.74 | 0.006 |
| Groups | ||||||
| Continuous | 4 | 0.35 (0.28, 0.41) | 0% | 0.400 | 10.12 | 0.000 |
| Categorical | 3 | 1.61 (1.26, 2.05) | 0% | 0.900 | 3.80 | 0.000 |
| Region | ||||||
| AMR | 4 | 0.32 (0.24, 0,40) | 62% | 0.050 | 8.29 | 0.000 |
| EUR | 4 | 0.40 (0.33, 0.47) | 98% | 0.000 | 10.50 | 0.000 |
| Asia | 2 | 0.44 (0.34, 0.54) | 95% | 0.000 | 8.59 | 0.000 |
| EMR | 2 | 0.36(0.21, 0.52) | 22% | 0.260 | 4.61 | 0.000 |
| Study period | ||||||
| Less than 10 years | 11 | 1.12 (0.94, 1.35) | 97% | 0.000 | 1.27 | 0.200 |
| 10 years or more | 2 | 2.95 (2.47, 3.52) | 92% | 0.001 | 12.01 | 0.000 |
| Adjustment for family history of CRC | ||||||
| Yes | 8 | 1.01 (0.82, 1.24) | 97% | 0.000 | 0.06 | 0.950 |
| No | 5 | 1.31 (1.10, 1.56) | 55% | 0.060 | 3.01 | 0.003 |
| Adjustment for education level | ||||||
| Yes | 8 | 1.11 (0.89, 1.39) | 98% | 0.000 | 0.93 | 0.350 |
| No | 5 | 1.12 (0.90, 1.39) | 75% | 0.003 | 1.04 | 0.300 |
| Adjustment for comorbidities | ||||||
| Yes | 5 | 1.08 (0.97, 1.20) | 64% | 0.030 | 1.41 | 0.160 |
| No | 8 | 1.18 (0.92, 1.50) | 96% | 0.000 | 1.28 | 0.200 |
| Adjustment for physical activity | ||||||
| Yes | 9 | 1.11 (0.89, 1.39) | 95% | 0.000 | 0.93 | 0.350 |
| No | 4 | 1.13 (1.07,1.20) | 0% | 0.890 | 4.38 | 0.000 |
| Adjustment for BMI | ||||||
| Yes | 5 | 1.60 (1.54, 1.67) | 96% | 0.000 | 23.81 | 0.000 |
| No | 2 | 0.86 (0.78, 0.96) | 92% | 0.001 | 2.84 | 0.004 |